Journal
JOURNAL OF CLINICAL LIPIDOLOGY
Volume 10, Issue 4, Pages 860-869Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2016.02.018
Keywords
Cholesterol; Lipoproteins; Hypercholesterolemia; Mipomersen; Pediatrics
Categories
Funding
- Sanofi Genzyme
- AstraZeneca
- Pfizer Pharmaceuticals
- Merck
- Sanofi
- Regeneron
- Amgen
- Genzyme/Isis Pharmaceuticals
Ask authors/readers for more resources
BACKGROUND: Homozygous familial hypercholesterolernia (HoFH) is a rare, inherited condition resulting in severely elevated low-density lipoprotein cholesterol levels (LDL-C) leading to premature cardiovascular disease and, often, death. Mipomersen is an antisense oligonucleotide that inhibits apolipoprotein B (apo B) synthesis, lowering LDL-C levels. Mipomersen has demonstrated efficacy in adult HoFH patients, possibly providing a therapeutic option for pediatric patients. Study objectives were to summarize mipomersen efficacy and safety in the pediatric cohort of a phase 3 randomized controlled trial (RCT) and subsequent open-label extension study (OLE). METHODS: Seven patients aged 12-18 years were randomized to 200-mg mipomersen or placebo weekly (26 weeks) and received mipomersen in the OLE (52 or 104 weeks). Plasma LDL-C and apo B concentrations and adverse events were assessed. RESULTS: All pediatric patients completed the RCT and entered OLE. The 3 mipomersen patients in the RCT experienced mean reductions from baseline to RCT end of 42.7% and 46.1% for LDL-C and apo B, respectively. Of the 4 placebo patients, 3 responded well to mipomersen during OLE, with reductions in LDL-C of 26.5%-42.1%. Three patients completed OLE treatment, and 4 patients discontinued therapy due to adverse events. Lipid level fluctuations were observed and were likely due to poor compliance. CONCLUSIONS: Long-term mipomersen treatment was successful regarding efficacy parameters for pediatric HoFH patients. The safety profile was consistent with other phase 3 clinical trials. Long-term compliance was an issue. Measures supporting adherence should be encouraged. (C) 2016 Sanofi-Genzyme. Published by Elsevier Inc. On behalf of National Lipid Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available